Answers are grounded in this paper and cite their sources.
High-throughput screening identifies lead JAK2 inhibitor through molecular dynamics simulation, suggesting potential therapeutic implications.
Purpose: To investigate the lead molecule for inhibition of JAK2 using high-throughput screening and molecular dynamics simulation.Methods: The MCULE database was used to screen 5 million ligands in a structure-based mode. The ligand hits were ranked according to VINA scores. Further filtration was achieved by approaches like MCULE-Toxicity Checker, Zero-RO5-Violation-Check, synthetic accessibility and overall pharmacokinetic features. Stability of the JAK2-inhibitor-complex was confirmed by molecular dynamics simulation of 120 ns, which used the AMBER14 force field in YASARA Structure-21.8.27. W.64.Results: The top molecule, 4-pyrimidinamine, 2,6-dimethyl-5-(2,4,5-trimethylpyrido (2,3-d) pyrimidin-7- yl), demonstrated strong binding with JAK2 involving 17 amino acid residues, 16 of which overlapped with the reference (PDB: 3JY9). It successfully passed all screening tests. The RMSD-time plot indicated that equilibrium was reached around 20 ns. Throughout the simulation from 20 to 120 ns, thebackbone RMSD fluctuations remained within a narrow range of 1.0 – 1.7 Å.Conclusion: The ligand, 4-pyrimidinamine, 2,6-dimethyl-5-(2,4,5-trimethylpyrido (2,3-d) pyrimidin-7-yl), meets the ADMET criteria. Also, an extended 120 ns Molecular Dynamics Simulation confirms the feasibility of the 'JAK2-Top ligand' complex. This ligand is a promising lead for designing inhibitors against JAK2 and should be further evaluated in future laboratory experiments.
No takes yet. Share an insight, caveat, or question.
Zahed et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: